Acute myeloid leukemia (AML) is a malignant hematological disease characterized by the clonal proliferation of myeloid progenitor cells and high heterogeneity. The development and progression of AML are closely associated with alterations in T cell phenotype and function. These changes can lead to aberrancies in the T cell population, ultimately resulting in immune dysfunction ofthe body. In recent years, researchers have utilized the anti-tumor activity of T cells in the treatment of AML, and it has been observed that the functional recovery of T cells in patients exerts a pronounced inhibitory effect on leukemia cells. At present, T cell immunotherapy for AML includes tumor infiltrating lymphocyte (TIL) therapy, bispecific antibody-recruited T cell therapy, immune checkpoint inhibitor (ICI) therapy, chimeric antigen receptor T-cell (CAR-T) therapy, and tumor-specific receptor gene-transduced T cell (TCR-T) therapy. This review comprehensively summarizes recent domestic and international advancements in T cell immunotherapy research, offering anoverview of the therapeutic efficacy and mechanisms of T cell immunotherapy on AML. The objective is to elucidate new potential strategies for the clinical treatment of AML.